Back to results
US 2010/0166837 A1Published application
1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation
AssigneeEldrug S.A.
InventorJohn Matsoukas
Life of this patent
Estimating the term…
Abstract
The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds in hydrophilic or lipophilic form, which are useful as angiotensin II ATI receptor antagonists suitable for transdermal delivery. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases.
Claims36
A compound of formula I,
- wherein
- R is H, halogen;
- X is alkyl, alkenyl, —(CH2)vCOOR1 or CH═CH—(CH2)vCOOR1, where v is 0 to 10;
- or
- R and X are linked so as to form a fused benzimidazole system;
- R1 is H, alkyl, aralkyl, trityl, halogen, haloalkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, aryloxy alkoxyalkoxy, cyano, hydroxy, hydroxyalkyl, nitro, tetrazolyl, oxadiazolyl, triazolyl, OCH(CH3)—OCOO-cyclohexyl, cycloanhydride or methyl-5-methyl-[1,3]-dioxolane;
- Y is H, CH2O-alkyl, CH2S-alkyl, CH2-halogen, CH2OH, CH2SH, CHO, COOH or halogen;
- W1 and W2 are each independently —(CH2)n—K—Z—Z1, where n is 1 to 5;
- K is biphenyl or monophenyl;
- Z is tetrazolyl or COO—;
- Z1 is H, trityl, halotrityl, CH2Ph, COOH, COO-alkyl or CH(Ph)2, wherein each Ph group is optionally substituted by one or more halogens;
- and
- E is an anion;
- or a pharmaceutically acceptable salt thereof.
11 more elements
2-13. (canceled)
-19. (canceled)
A compound of formula II or formula III,
- wherein
- R is H, halogen;
- X is alkenyl, —(CH2)vCOOR1 or CH═CH—(CH2)vCOOR1, where v is 0 to 10;
- or
- R and X are linked so as to form a fused benzimidazole system;
- or
- X is alkyl, when Z1 is halotrityl, COOH, COO-alkyl, CH2(C6H4-Hal) or CH(Ph)2, wherein each Ph group is optionally substituted by one or more halogens;
- R1 is H, alkyl, aralkyl, trityl, halogen, haloalkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, aryloxy alkoxyalkoxy, cyano, hydroxy, hydroxyalkyl, nitro, tetrazolyl, oxadiazolyl, triazolyl, OCH(CH3)—OCOO-cyclohexyl, cycloanhydride or methyl-5-methyl-[1,3]-dioxolane;
- Y is H, CH2O-alkyl, CH2S-alkyl, CH2-halogen, CH2OH, CH2SH, COOH, halogen or CHO;
- W1 is —(CH2)n—K—Z—Z1, where n is 1 to 5;
- K is biphenyl or monophenyl;
- Z is tetrazolyl or COO—;
- and
- Z1 is H, trityl, halotrityl, CH2Ph, COOH, COO-alkyl, or CH(Ph)2, wherein each Ph group is optionally substituted by one or more halogens;
- or a pharmaceutically acceptable salt thereof.
12 more elements
(canceled)
-34. (canceled)
-40. (canceled)
(canceled)
-55. (canceled)
-60. (canceled)
Dependencies are inferred from the claim text.